ZA953976B - 11,21-bisphenyl-19-norpregnane derivatives - Google Patents

11,21-bisphenyl-19-norpregnane derivatives

Info

Publication number: ZA953976B
Authority: ZA; South Africa
Prior art keywords: nr5r6; alkyl; bisphenyl; son; optionally substituted
Prior art date: 1994-05-19

Application number

ZA953976A

Other languages

English (en)

Inventor

Ronald Gebhard

Hendrikus Andrianus Anto Voort

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-19

Filing date

1995-05-16

Publication date

1996-01-19

1995-05-16 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1996-01-19 Publication of ZA953976B publication Critical patent/ZA953976B/xx

Links

125000000217 alkyl group Chemical group 0.000 abstract 4
239000003862 glucocorticoid Substances 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Seasonings (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

ZA953976A 1994-05-19 1995-05-16 11,21-bisphenyl-19-norpregnane derivatives ZA953976B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP94201431		1994-05-19

Publications (1)

Publication Number	Publication Date
ZA953976B true ZA953976B (en)	1996-01-19

Family

ID=8216894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA953976A ZA953976B (en)	1994-05-19	1995-05-16	11,21-bisphenyl-19-norpregnane derivatives

Country Status (20)

Country	Link
US (1)	US5620966A (de)
EP (1)	EP0683172B1 (de)
JP (1)	JP3814312B2 (de)
KR (1)	KR100359474B1 (de)
CN (1)	CN1042539C (de)
AT (1)	ATE156836T1 (de)
AU (1)	AU701616B2 (de)
BR (1)	BR9502085A (de)
CA (1)	CA2149496C (de)
DE (1)	DE69500542T2 (de)
DK (1)	DK0683172T3 (de)
ES (1)	ES2106616T3 (de)
FI (1)	FI112491B (de)
GR (1)	GR3025225T3 (de)
HU (1)	HU217429B (de)
NO (1)	NO304379B1 (de)
NZ (1)	NZ272143A (de)
PL (1)	PL180481B1 (de)
RU (1)	RU2152952C2 (de)
ZA (1)	ZA953976B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL118974A (en) *	1995-08-17	2001-09-13	Akzo Nobel Nv	History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
HK1042889B (zh)	1999-04-30	2006-12-29	辉瑞产品公司	糖皮质激素受体调制剂
US7713989B2 (en)	2000-04-27	2010-05-11	Dow Robert L	Glucocorticoid receptor modulators
ES2246292T3 (es)	2000-10-30	2006-02-16	Pfizer Products Inc.	Moduladores de receptor glucocorticoide.
EP1285927A3 (de)	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
AU2002366217A1 (en)	2001-11-23	2003-06-10	Akzo Nobel N.V.	Treatment of major depressive disorder using glucocorticoid receptor antagonists
US8080682B2 (en)	2006-08-24	2011-12-20	University Of Tennessee Research Foundation	Substituted acylanilides and methods of use thereof
US7250408B2 (en)	2002-12-16	2007-07-31	Bayer Schering Pharma Ag	Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
PT1601363E (pt) *	2003-03-11	2012-08-17	Trophos	Aplicação como medicamentos de derivados da colest-4-en-3- ona, composições farmacêuticas que os contêm e novos derivados
HUE052574T2 (hu)	2012-07-13	2021-05-28	Oncternal Therapeutics Inc	Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
WO2016140867A1 (en)	2015-03-02	2016-09-09	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
US10610534B2 (en)	2015-03-30	2020-04-07	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
CN105254697A (zh) *	2015-11-17	2016-01-20	湖南成大生物科技有限公司	△16甾体类化合物的制备方法
KR102197526B1 (ko)	2016-01-19	2020-12-31	코어셉트 쎄라퓨틱스 인코포레이티드	이소성 쿠싱 증후군의 감별 진단
EP3214092A1 (de) *	2016-03-04	2017-09-06	Bayer Pharma Aktiengesellschaft	Prodrugs vom selektiven progesteronrezeptormodulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-on
MX393313B (es)	2017-06-20	2025-03-24	Corcept Therapeutics Inc	Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
CN114456223B (zh) *	2022-01-24	2023-07-21	湖南科益新生物医药有限公司	3-缩酮的合成方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1515284A (en) *	1974-05-21	1978-06-21	Gastaud J	Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) *	1982-06-11	1985-07-19	Roussel Uclaf	Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2522328B1 (fr) *	1982-03-01	1986-02-14	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2639045B2 (fr) *	1982-03-01	1994-07-29	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
EP0116974B1 (de) *	1983-02-18	1986-10-29	Schering Aktiengesellschaft	11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
FR2549067B1 (fr) *	1983-06-14	1985-12-27	Roussel Uclaf	Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
US4780461A (en) *	1983-06-15	1988-10-25	Schering Aktiengesellschaft	13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3410880A1 (de) *	1984-03-21	1985-10-03	Schering AG, Berlin und Bergkamen, 1000 Berlin	17-substituierte estradiene und estratriene
DE3506785A1 (de) *	1985-02-22	1986-08-28	Schering AG, Berlin und Bergkamen, 1000 Berlin	11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4771042A (en) *	1985-11-25	1988-09-13	The Upjohn Company	Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
FR2598421B1 (fr)	1986-05-06	1988-08-19	Roussel Uclaf	Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) *	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) *	1986-09-17	1988-09-27	Research Triangle Institute	17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
ATE85342T1 (de) *	1987-12-12	1993-02-15	Akzo Nv	11-arylsteroid-derivate.
JP2785023B2 (ja) *	1987-12-30	1998-08-13	ルセル―ユクラフ	１７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
US4954490A (en) *	1988-06-23	1990-09-04	Research Triangle Institute	11 β-substituted progesterone analogs
DE3822770A1 (de) *	1988-07-01	1990-01-04	Schering Ag	13-alkyl-11ss-phenylgonane
DE3832303A1 (de) *	1988-09-20	1990-04-12	Schering Ag	11ss-phenyl-14ssh-steroide
FR2643638B1 (fr) *	1989-02-24	1991-06-14	Roussel Uclaf	Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2644789B1 (fr) *	1989-03-22	1995-02-03	Roussel Uclaf	Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
JP3135564B2 (ja) *	1989-08-04	2001-02-19	シエーリングアクチエンゲゼルシヤフト	１１β―置換１６α，１７α―メチレン―エストラ―４，９―ジエン―３―オン
US5276023A (en) *	1989-08-08	1994-01-04	Roussel Uclaf	19-nor-steroid esters
FR2651435A1 (fr) *	1989-09-07	1991-03-08	Roussel Uclaf	Nouvelle utilisation de composes anti-progestomimetiques.
US5407928A (en) *	1990-08-15	1995-04-18	Schering Aktiengesellschaft	11β-aryl-gona-4,9-dien-3-ones
EP0712311B1 (de) *	1993-08-04	1998-10-07	Akzo Nobel N.V.	Antiglucocorticoidsteroide zur behandlung von angststörungen

1995
- 1995-05-16 AT AT95201268T patent/ATE156836T1/de not_active IP Right Cessation
- 1995-05-16 ES ES95201268T patent/ES2106616T3/es not_active Expired - Lifetime
- 1995-05-16 CA CA002149496A patent/CA2149496C/en not_active Expired - Fee Related
- 1995-05-16 EP EP95201268A patent/EP0683172B1/de not_active Expired - Lifetime
- 1995-05-16 DK DK95201268.0T patent/DK0683172T3/da active
- 1995-05-16 DE DE69500542T patent/DE69500542T2/de not_active Expired - Fee Related
- 1995-05-16 ZA ZA953976A patent/ZA953976B/xx unknown
- 1995-05-17 NZ NZ272143A patent/NZ272143A/en unknown
- 1995-05-18 PL PL95308666A patent/PL180481B1/pl not_active IP Right Cessation
- 1995-05-18 KR KR1019950012374A patent/KR100359474B1/ko not_active Expired - Fee Related
- 1995-05-18 BR BR9502085A patent/BR9502085A/pt not_active IP Right Cessation
- 1995-05-18 CN CN95105395A patent/CN1042539C/zh not_active Expired - Fee Related
- 1995-05-18 FI FI952424A patent/FI112491B/fi active
- 1995-05-18 HU HU9501461A patent/HU217429B/hu not_active IP Right Cessation
- 1995-05-18 NO NO951968A patent/NO304379B1/no unknown
- 1995-05-18 JP JP12005195A patent/JP3814312B2/ja not_active Expired - Fee Related
- 1995-05-18 RU RU95107892/04A patent/RU2152952C2/ru not_active IP Right Cessation
- 1995-05-18 AU AU20133/95A patent/AU701616B2/en not_active Ceased
- 1995-05-19 US US08/445,119 patent/US5620966A/en not_active Expired - Fee Related
1997
- 1997-10-30 GR GR970402861T patent/GR3025225T3/el unknown

Also Published As

Publication number	Publication date
FI952424A0 (fi)	1995-05-18
DK0683172T3 (da)	1998-03-30
FI112491B (fi)	2003-12-15
US5620966A (en)	1997-04-15
PL180481B1 (pl)	2001-02-28
JP3814312B2 (ja)	2006-08-30
RU2152952C2 (ru)	2000-07-20
ATE156836T1 (de)	1997-08-15
CA2149496C (en)	2006-12-19
NZ272143A (en)	1995-11-27
JPH07316187A (ja)	1995-12-05
DE69500542D1 (de)	1997-09-18
HU9501461D0 (en)	1995-06-28
CN1126727A (zh)	1996-07-17
NO951968D0 (no)	1995-05-18
KR100359474B1 (ko)	2003-03-12
CN1042539C (zh)	1999-03-17
EP0683172B1 (de)	1997-08-13
HUT71804A (en)	1996-02-28
CA2149496A1 (en)	1995-11-20
AU701616B2 (en)	1999-02-04
PL308666A1 (en)	1995-11-27
EP0683172A1 (de)	1995-11-22
GR3025225T3 (en)	1998-02-27
DE69500542T2 (de)	1998-01-02
ES2106616T3 (es)	1997-11-01
BR9502085A (pt)	1996-03-05
RU95107892A (ru)	1997-02-10
AU2013395A (en)	1995-11-30
FI952424L (fi)	1995-11-20
KR950032267A (ko)	1995-12-20
HU217429B (hu)	2000-01-28
NO951968L (no)	1995-11-20
NO304379B1 (no)	1998-12-07

Publication	Publication Date	Title
HU9501461D0 (en)	1995-06-28	11,21-bisphenyl-19-norpregnane derivatives
TW427887B (en)	2001-04-01	Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
NZ332762A (en)	2000-09-29	Isobutylgaba and its derivatives for the treatment of pain
GR3017996T3 (en)	1996-02-29	17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION.
IL145005A0 (en)	2002-06-30	4-OXO-4, 7-DIHYDRO-THIENO[2,3-b] PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
PH31453A (en)	1998-11-03	7-(2-Aminoethyl)- benzothiazolones.
ES2063300T3 (es)	1995-01-01	Derivado de acido aminobencensulfonico.
IE890177L (en)	1989-07-21	Piperidinyl derivatives
IL136735A0 (en)	2001-06-14	Substituted 2-benzylamino-2-phenyl-acetamide compounds
EP0882728A4 (de)	1999-03-24	1-methylcarbapenem-derivate
IL108085A0 (en)	1994-04-12	Serotoninergic ergoline derivatives their preparation and pharmacutical compositions containing them
TW244336B (de)	1995-04-01
EP0785190A3 (de)	1997-08-27
HUT64345A (en)	1993-12-28	Methods for producing amino-alkyl-pyrrolidinyl-thio-carbapeneme derivatives and pharmaceutical preparatives containing them as active agent
TW275629B (de)	1996-05-11
ATE122892T1 (de)	1995-06-15	Zusammensetzung gegen katarakt.
MX9705379A (es)	1997-10-31	Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis vasodilatadora.